logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
BLTE
Belite Bio, Inc
161.43
1 x 158.68
1 x 160.10
bid
ask
+
0.35
0.22%
10:01 AM
timesize
Ytd0.92%
1y170.49%
160.14
day range
161.43
59.12
52 week range
200.00
Open161.43Prev Close161.08Low160.14High161.43Mkt Cap6.46B
Vol13.59KAvg Vol190.53KEPS-1.87P/E-86.14Forward P/E227.27
Beta-1.23Short Ratio5.37Inst. Own23.65%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg146.65200-d Avg146.901yr Est210.50

BLTE News

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
globenewswire.com
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Seco

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
globenewswire.com
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
marketbeat.com
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease

Belite Bio NASDAQ: BLTE Chief Medical Officer Hendrik Scholl said the company is advancing its lead

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
globenewswire.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
globenewswire.com
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
globenewswire.com
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Co

Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Trans

Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Trans

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
seekingalpha.com
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript

Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript

Belite Bio Q1 Earnings Call Highlights
marketbeat.com
Belite Bio Q1 Earnings Call Highlights

Belite Bio NASDAQ: BLTE said it has begun a rolling New Drug Application submission to the U.S. Food

Earnings Scheduled For May 20, 2026
benzinga.com
Earnings Scheduled For May 20, 2026

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Co

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
globenewswire.com
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Co

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
globenewswire.com
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Sy

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “

Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
globenewswire.com
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript
seekingalpha.com
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
globenewswire.com
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference o

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical stage develo

Wan-Shan Chen Sells 1,100 Shares of Belite Bio (NASDAQ:BLTE) Stock
defenseworld.net
Wan-Shan Chen Sells 1,100 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) Director Wan-Shan Chen sold 1,100 sh

Belite Bio (NASDAQ:BLTE) CFO Hao-Yuan Chuang Sells 6,200 Shares of Stock
defenseworld.net
Belite Bio (NASDAQ:BLTE) CFO Hao-Yuan Chuang Sells 6,200 Shares of Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) CFO Hao-Yuan Chuang sold 6,200 share

Earnings Scheduled For March 2, 2026
benzinga.com
Earnings Scheduled For March 2, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Earnings Scheduled For November 10, 2025
benzinga.com
Earnings Scheduled For November 10, 2025
benzinga.com
Earnings Scheduled For August 11, 2025
benzinga.com
Earnings Scheduled For March 17, 2025